Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Satellos Bioscience Inc T.MSCL

Alternate Symbol(s):  MSCLF

Satellos Bioscience Inc. is a Canada-based a drug discovery and development company with a focus on muscle regeneration. The Company is focused on developing medicines to treat degenerative muscle conditions. Its MyoReGenX platform is specifically designed to recreate the specialized muscle stem cell niche in vitro. MyoReGenX platform enables to map pathways which modulate muscle repair and... see more

TSX:MSCL - Post Discussion

View:
Post by db2067 on Nov 26, 2021 8:05am

Skymount

They are still negotiating with Skymount Medical, I figure the longer it takes then the more comprehensive the deal/JV is that they are ironing out. They said the scopre may expand:

"There is potential to expand the scope of this collaboration in the future based on certain events and circumstances. Negotiations with Skymount are ongoing"

June 24, 2021 Satellos / iCo Therapeutics PROPOSED PLAN OF ARRANGEMENT "iCo is currently exploring partnering options and pursuing funding sources to initiate its intended Phase 2 trial of iCo019 during 2021. On December 31, 2020 iCo announced that it had executed a non-binding Memorandum of Understanding with Skymount Medical Inc. (“Skymount”) to develop iCo-019. Skymount agrees to initially commit up to US$550,000 to the iCo-019 program. These funds will support preclinical studies assessing iCo-019’s potential as a treatment for infections related to COVID-19. There is potential to expand the scope of this collaboration in the future based on certain events and circumstances. Negotiations with Skymount are ongoing"
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities